Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the
developed world. Despite available treatment, 25% of children in San Diego County
appropriately treated for KD develop coronary artery abnormalities that may lead to
complications later in life, including heart attack. Although the investigators can identify
children with KD that have these coronary artery abnormalities, there is no approved
additional treatment to decrease coronary artery inflammation and arrest or prevent damage to
the coronary arteries. Anakinra, a therapy that blocks the high levels of interleukin 1 (IL1)
that lead to inflammation during acute KD, has been shown in the KD mouse model to prevent
the development of coronary artery damage. Therefore, the investigators propose to study the
safety and activity of anakinra in infants and children < 2 years old with coronary artery
abnormalities from KD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
Boston Children's Hospital Boston Children’s Hospital Cedars-Sinai Medical Center